FORTA-Based Pharmacist Review Cuts Medication Problems in Older Cancer Patients
This trial provides the first randomized evidence that a pharmacist-led, FORTA-guided medication review substantially improves prescribing quality in older cancer patients with polypharmacy during oncological rehabilitation.
📅 Journal publication: Dec 2026(online Sep 23, 2026)·Last updated: Oct 6, 2026
Pharmacist-led reviews reduce inappropriate medication in older cancer patients.
Older cancer patients often experience polypharmacy, leading to medication-related issues. Improving medication quality can enhance their overall care. The pharmacist-led medication review resulted in a mean FORTA score reduction of 3.7 points and decreased inappropriate medication, underuse, and overuse by 41.3%, 35.5%, and 30.7%, respectively. This study supports pharmacist-led interventions using the FORTA list to optimize medication regimens in older cancer patients, improving safety and efficacy. Pharmacist-led medication reviews significantly improve medication quality in older cancer patients with polypharmacy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Citation:Degen M, Kopp-Schneider A, Vlaski T, et al. Cancer co-medication quality in older patients with polypharmacy: A large randomized trial testing a medication review versus usual care. Journal of internal medicine. 2026;300(6):802-820. doi:10.1111/joim.70161